Six-month depot formulation of leuprorelin acetate in the treatment of prostate cancer. Review uri icon

Overview

abstract

  • Hormonal deprivation therapy is well established for the treatment of locally advanced and metastatic prostate cancer, as well as the adjuvant treatment of some patients with localized disease. Long-acting gonadotropin releasing hormone (GnRH) agonists have become a mainstay of androgen deprivation therapy, due to their efficacy, tolerability, and convenience of use. One-month, 3-month, and 4-month depot leuprorelin formulations are well established and widely used to this end. Recently, a 6-month depot leuprorelin has been approved for use in advanced and metastatic prostate cancer patients. With similar efficacy and side effect profiles to earlier formulations, 6-month depot leuprorelin is a convenient treatment option for these patients. This review will highlight the role of GnRH agonists in the treatment of prostate cancer with a focus on the clinical efficacy, pharmacology, and patient-focused outcomes of the newer 6-month 45 mg depot leuprorelin formulation in comparison to available shorter-acting products.

publication date

  • June 9, 2009

Research

keywords

  • Antineoplastic Agents, Hormonal
  • Leuprolide
  • Prostatic Neoplasms

Identity

PubMed Central ID

  • PMC2697591

Scopus Document Identifier

  • 77349087142

Digital Object Identifier (DOI)

  • 10.2147/cia.s4885

PubMed ID

  • 19554097

Additional Document Info

volume

  • 4